SCHEMBL1623570

SCHEMBL1623570

NCC1CCN(c2nc(-c3ccccc3O)nc3ccc(F)cc23)C1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 5/20 0.55
SMAD3 P84022 1/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TSHR P16473 1/20 0.45
BPTF Q12830 1/20 0.45
ADORA2A P29274 1/20 0.41
MAOB P27338 1/20 0.41
HTR6 P50406 1/20 0.41
HIF1A Q16665 2/20 0.41
IRAK4 Q9NWZ3 1/20 0.39
CASR P41180 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SSTR2 P30874 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1623569 1.00 CHEK2 (0.55) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL1084207 0.87 SMAD3 (0.54) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL183923 0.87 CHEK2 (0.58) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL183922 0.87 CHEK2 (0.58) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL5499286 0.86 CHEK2 (0.50) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL5499288 0.86 CHEK2 (0.50) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL4011640 0.86 CHEK2 (0.54) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL4011654 0.86 CHEK2 (0.54) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL13769449 0.86 CHEK2 (0.62) CHEK2SMAD3MEN1KMT2AALDH1A1
SCHEMBL1084648 0.85 SMAD3 (0.52) CHEK2SMAD3MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
US-20090312342-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2009-12-17 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312342-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885SMAD3 4194/4885MEN1 2548/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885SMAD3 4194/4885MEN1 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.